Create a Profile
Create a Profile
Get In Touch Mobile
Accel Research Sites to attend World Vaccine Congress
Accel Research Sites emerged as a leader in vaccine clinical trials during the COVID-19 pandemic, driving thought leadership in the industry.
Now, the company is taking it to the world stage.
Accel Research Sites will be attending the World Vaccine Congress from April 18 to 21, 2022, in Washington, D.C. The preeminent event has been called “the most important vaccine event of the year” and is the largest, most established gathering in the field. Accel’s presence at the event will allow them to make connections and share insights with some of the largest sponsor companies, CROs, site networks and vendors in the world as they continue to drive the future of medicine.
“At Accel, we pride ourselves on always going further. We are so excited to attend the World Vaccine Congress to strengthen our relationships and start new ones with many professionals in the vaccine world,” said Lora Parahovnik, CEO. “We hope that attending this important event will help us build relationships and stay on the cutting edge of vaccine research.”
The World Vaccine Congress will take place at the Marriott Marquis in Washington, D.C. Attendees will have the opportunity to hear speakers on a variety of trending topics within the vaccine industry, visit booths from pharmaceutical and biotech leaders, and connect with peers throughout the four-day experience.
Over the past 21 years, the World Vaccine Congress has become the world’s leading summit on vaccines. The event covers the entire vaccine chain, from research to manufacturing.
Accel Research Sites is a leading multi-therapeutic network of clinical research sites. The company works with some of the top pharmaceutical, biotechnology and medical device companies in the world to deliver exceptional execution in clinical trials with the goal of advancing healthcare.
To learn more about the World Vaccine Congress click here.
Ready to be part of healthcare history? Find the right clinical trial for you.